PET Imaging of αvβ3 Expression in Cancer Patients

Methods in Molecular Biology

Volumn 680, Issue , 2011, Pages 183-200

  Beer, Ambros J ^a   Schwaiger, Markus ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

angiogenesis; integrin alpha v beta 3; molecular imaging; PET; RGD; 18F Galacto RGD

Indexed keywords

FLUORINE; TRACER; VITRONECTIN RECEPTOR;

ARTICLE; COMPARATIVE STUDY; GENE EXPRESSION; HUMAN; METABOLISM; METHODOLOGY; NEOPLASM; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY;

FLUORINE RADIOISOTOPES; GENE EXPRESSION; HUMANS; INTEGRIN ALPHAVBETA3; MAGNETIC RESONANCE IMAGING; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOACTIVE TRACERS;

MLCS; MLOWN;

EID: 79952132377     PISSN: 10643745     EISSN: 19406029     Source Type: Book Series    
DOI: 10.1007/978-1-60761-901-7_13     Document Type: Chapter

References (49)

1. Hood, J. D. and Cheresh, D. A. (2002) Role of integrins in cell invasion and migration. Nat. Rev. Cancer 2, 91–100.
2. Ruoslahti, E. (1996) RGD and other recognition sequences for integrins. Annu. Rev. Cell Dev. Biol. 12, 697–715.
3. Xiong, J. P., Stehle, T., Zhang, R., et al. (2002) Crystal structure of the extracellular segment of integrin αvβ3 in complex with an Arg-Gly-Asp ligand. Science 296, 151–5.
4. Cai, W. and Chen, X. (2006) Anti-angiogenic cancer therapy based on integrin αvβ3 antagonism. Anti-Cancer Agents Med. Chem. 6, 407–28.
5. Hynes, R. O. (2002) A reevaluation of integrins as regulators of angiogenesis. Nat. Med. 8, 918–21.
6. Kerbel, R. S. (2006) Antiangiogenic therapy: a universal chemosensitization strategy for cancer? Science 312, 1171–5.
7. Hurwitz, H., Fehrenbacher, L., Novotny, W., et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350, 2335–42.
8. Ruoslahti, E. and Pierschbacher, M. D. (1987) New perspectives in cell adhesion: RGD and integrins. Science 238, 491–7.
9. Haubner, R., Finsinger, D., and Kessler, H. (1997) Stereoisomeric peptide libraries and peptidomimetics for designing selective inhibitors of the αvβ3 integrin for a new cancer therapy. Angew. Chem. Int. Ed. Engl. 36, 1374–89.
10. Haubner, R., Wester, H. J., Reuning, U., et al. (1999) Radiolabeled αvβ3 integrin antagonists: a new class of tracers for tumor targeting. J. Nucl. Med. 40, 1061–71.
11. 18 F]Galacto-RGD: synthesis, radiolabeling, metabolic stability, and radiation dose estimates. Bioconjug. Chem. 15(1), 61–9.
12. Kenny, L. M., Coombes, R. C., Oulie, I., Contractor, K. B., Miller, M., Spinks, T. J., McParland., B., Cohen, P. S., Hui, A. M., Palmieri, C., Osman, S., Glaser, M., Tur-ton, D., Al-Nahhas, A., and Aboagye, E. O. (2008, Jun) Phase I trial of the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand 18F-AH111585 in breast cancer patients. J. Nucl. Med. 49(6), 879–86.
13. 18 F]fluorinated aldehyde-containing prosthetic groups. Bioconjug. Chem. 19(4), 951–7.
14. 18 F-galacto-RGD, a new radiotracer for imaging αvβ3 expression. J. Nucl. Med. 47, 763–9.
15. 18 F]Galacto-RGD PET. J. Nucl. Med. 48(S2), 406 (abstract).
16. Carson, R. E. (2003) Tracer kinetic modelling in PET. In Positron emission tomography – basic science and clinical practice, Valk, P. E., Bailey, D. L., Townsend, D. W., and Maisey, M. N., (Eds.), 2nd ed. Springer, London, pp. 147–80.
17. Slifstein, M. and Laruelle, M. (2001) Models and methods for derivation of in vivo neu-roreceptor parameters with PET and SPECT reversible radiotracers. Nucl. Med. Biol. 28, 595–608.
18. 18 F]diprenorphine kinetics in the human brain with compartmental and non-compartmental modeling approaches. Neuroimage 22, 1523–33.
19. Beer, A. J., Haubner, R., Goebel, M., et al. (2005) Biodistribution and pharmacokinet-ics of the αvβ3 selective tracer 18F Galacto-RGD in cancer patients. J. Nucl. Med. 46, 1333–41.
20. Schnell, O., Krebs, B., Wagner, E., Romagna, A., Beer, A. J., Grau, S. J., Thon, N., Goetz, C., Kretzschmar, H. A., Tonn, J. C., and Goldbrunner, R. H. (2008, Jul) Expression of integrin αvβ3 in gliomas correlates with tumor grade and is not restricted to tumor vasculature. Brain Pathol. 18(3), 378–86.
21. 18 F]Galacto-RGD identifies the level of integrin αvβ3 expresssion in man. Clin. Cancer Res. 12, 3942–9.
22. 18 F]Galacto-RGD PET for imaging of αvβ3 expression on neovas-culature in patients with squamous cell carcinoma of the head and neck. Clin. Cancer Res. 13(22 Pt 1), 6610–6.
23. Beer, A. J., Lorenzen, S., Metz, S., Herrmann, K., Watzlowik, P., Wester, H. J., Peschel, C., Lordick, F., and Schwaiger, M. (2008, Jan) Comparison of integrin αvβ3 expression and glucose metabolism in primary and metastatic lesions in cancer patients: a PET study using 18F-galacto-RGD and 18F-FDG. J. Nucl. Med. 49(1), 22–9.
24. Beer, A. J. and Schwaiger, M. (2008, Jun 4) Imaging of integrin αvβ3 expression. Cancer Metastasis Rev. 27, 631–44.
25. Makowski, M. R., Ebersberger, U., Nekolla, S., and Schwaiger, M. (2008, Mar 27) In vivo molecular imaging of angiogenesis, targeting αvβ3 integrin expression, in a patient after acute myocardial infarction. Eur. Heart J. 29, 2201.
26. 18 F]Galacto-RGD. PLoS Med. 2(3), e70.
27. Pichler, B. J., Kneilling, M., Haubner, R., Braumüller, H., Schwaiger, M., Röcken, M., and Weber, W. A. (2005, Jan) Imaging of delayed-type hypersensitivity reaction by PET and 18F-galacto-RGD. J. Nucl. Med. 46(1), 184–9.
28. Bach-Gansmo, T., Danielsson, R., Saracco, A., Wilczek, B., Bogsrud, T. V., Fangberget, A., Tangerud, A., and Tobin, D. (2006, Sep) Integrin receptor imaging of breast cancer: a proof-of-concept study to evaluate 99mTc-NC100692. J. Nucl. Med. 47(9), 1434–9.
29. Weber, W. A. (2006) Positron emission tomography as an imaging biomarker. J. Clin. Oncol. 24(20), 3282–92.
30. Buck, A. K., Nekolla, S., Ziegler, S., Beer, A., Krause, B. J., Herrmann, K., Scheidhauer, K., Wester, H. J., Rummeny, E. J., Schwaiger, M., and Drzezga, A. (2008, Aug) Spect/Ct. J. Nucl. Med. 49(8), 1305–19.
31. Sipkins, D. A., Cheresh, D. A., Kazemi, M. R., Nevin, L. M., Bednarski, M. D., and Li, K. C. (1998) Detection of tumor angiogenesis in vivo by αvβ3-targeted magnetic resonance imaging. Nat. Med. 4, 623–6.
32. Winter, P. M., Caruthers, S. D., Kassner, A., et al. (2003) Molecular imaging of angiogenesis in nascent Vx-2 rabbit tumors using a novel αvβ3-targeted nanoparticle and 1.5 tesla magnetic resonance imaging. Cancer Res. 63, 5838–43.
33. Schmieder, A. H., Winter, P. M., Caruthers, S. D., et al. (2005) Molecular MR imaging of melanoma angiogenesis with αvβ3-targeted paramagnetic nanoparticles. Magn. Reson. Med. 53, 621–7.
34. Thorek, D. L., Chen, A. K., Czupryna, J., and Tsourkas, A. (2006) Superparamagnetic iron oxide nanoparticle probes for molecular imaging. Ann. Biomed. Eng. 34, 23–38.
35. Zhang, C., Jugold, M., Woenne, E. C., et al. (2007) Specific targeting of tumor angiogenesis by RGD-conjugated ultrasmall superparamagnetic iron oxide particles using a clinical 1.5-T magnetic resonance scanner. Cancer Res. 67, 1555–62.
36. Spuentrup, E. and Botnar, R. M. (2006) Coronary magnetic resonance imaging: visualization of vessel lumen and the vessel wall and molecular imaging of arteriotrombosis. Eur. Radiol. 16, 1–14.
37. Jaffer, F. A. and Weissleder, R. (2004) Seeing within: molecular imaging of the cardiovascular system. Circ. Res. 94, 433–45.
38. Ellegala, D. B., Leong-Poi, H., Carpenter, J. E., et al. (2003) Imaging tumor angiogenesis with contrast ultrasound and microbub-bles targeted to αvβ3. Circulation 108, 336–41.
39. Kumar, C. C., Nie, H., Rogers, C. P., et al. (1997) Biochemical characterization of the binding of echistatin to integrin αvβ3 receptor. J. Pharmacol. Exp. Ther. 283, 843–53.
40. Hughes, M. S., Marsh, J. N., Zhang, H., et al. (2006) Characterization of digital wave-forms using thermodynamic analogs: detection of contrast-targeted tissue in vivo. IEEE Trans. Ultrason. Ferroelectr. Freq. Control 53, 1609–16.
41. Marsh, J. N., Partlow, K. C., Abendschein, D. R., Scott, M. J., Lanza, G. M., and Wickline, S. A. (2007) Molecular imaging with targeted perfluorocarbon nanoparticles: quantification of the concentration dependence of contrast enhancement for binding to sparse cellular epitopes. Ultrasound Med. Biol. 33(6), 950–8.
42. Bloch, S. H., Dayton, P. A., and Ferrara, K. W. (2004) Targeted imaging using ultrasound contrast agents. Progess and opportunities for clinical and research applications. IEEE Eng. Med. Biol. Mag. 23, 18–29.
43. Bremer, C., Bredow, S., Mahmood, U., et al. (2001) Optical imaging of matrix metalloproteinase-2 activity in tumors: feasibility study in a mouse model. Radiology 221, 523–9.
44. Chen, X., Conti, P. S., and Moats, R. A. (2004) In vivo near-infrared fluorescence imaging of integrin αvβ3 in brain tumor xenografts. Cancer Res. 64(21), 8009–14.
45. Jin, Z. H., Josserand, V., Foillard, S., Botu-ryn, D., Dumy, P., Favrot, M. C., and Coll, J. L. (2007) In vivo optical imaging of integrin αvβ3 in mice using multivalent or mono-valent cRGD targeting vectors. Mol. Cancer 6, 41.
46. von Wallbrunn, A., Holtke, C., Zuhlsdorf, M., Heindel, W., Schafers, M., and Bremer, C. (2007) In vivo imaging of integrin αvβ3 expression using fluorescence-mediated tomography. Eur. J. Nucl. Med. Mol. Imaging 34(5), 745–54 (Epub 2006 Nov 28).
47. Jaffer, F. A. and Weissleder, R. (2005) Molecular imaging in the clinical arena. JAMA 293, 855–62.
48. 18 F-labeled dimeric RGD peptide. Mol. Imaging 3, 96–104.
49. 18 F-FRGD2. J. Nucl. Med. 47, 113–21.